WO2008022015A3 - Retro-inverso incretin analogues, and methods of use thereof - Google Patents

Retro-inverso incretin analogues, and methods of use thereof Download PDF

Info

Publication number
WO2008022015A3
WO2008022015A3 PCT/US2007/075676 US2007075676W WO2008022015A3 WO 2008022015 A3 WO2008022015 A3 WO 2008022015A3 US 2007075676 W US2007075676 W US 2007075676W WO 2008022015 A3 WO2008022015 A3 WO 2008022015A3
Authority
WO
WIPO (PCT)
Prior art keywords
retro
inverso
incretin
methods
relates
Prior art date
Application number
PCT/US2007/075676
Other languages
French (fr)
Other versions
WO2008022015A2 (en
Inventor
William W Bachovchin
Hung-Sen Lai
David George Sanford
Original Assignee
Tufts College
William W Bachovchin
Hung-Sen Lai
David George Sanford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College, William W Bachovchin, Hung-Sen Lai, David George Sanford filed Critical Tufts College
Publication of WO2008022015A2 publication Critical patent/WO2008022015A2/en
Publication of WO2008022015A3 publication Critical patent/WO2008022015A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Abstract

One aspect of the present invention relates to synthetic analogues of a native peptide incretin hormone, e.g., glucagon-like peptide 1 (GLP-I), which in certain embodiments are rationally designed retro-inverso sequences with corrections for side-chain stereochemistry and terminus modifications for end-group effects. Another aspect of the invention relates to a method of treating a mammal suffering from diabetes, atherosclerosis, microangiopathy, kidney disorders, kidney failure, cardiac disease, diabetic retinopathy, ocular disorders, or blindness, comprising the step of administering a therapeutically effective amount of an incretin analogue of the present invention.
PCT/US2007/075676 2006-08-11 2007-08-10 Retro-inverso incretin analogues, and methods of use thereof WO2008022015A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83710506P 2006-08-11 2006-08-11
US60/837,105 2006-08-11

Publications (2)

Publication Number Publication Date
WO2008022015A2 WO2008022015A2 (en) 2008-02-21
WO2008022015A3 true WO2008022015A3 (en) 2008-10-23

Family

ID=39082991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075676 WO2008022015A2 (en) 2006-08-11 2007-08-10 Retro-inverso incretin analogues, and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2008022015A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US8900593B2 (en) 2007-02-15 2014-12-02 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US9018164B2 (en) 2005-11-07 2015-04-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9249206B2 (en) 2010-12-22 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9487571B2 (en) 2010-01-27 2016-11-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
CA2707861A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
AU2009274425B2 (en) 2008-06-17 2014-05-15 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
CN102459325B (en) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 Gip receptor-active glucagon compounds
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2015DN03795A (en) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
WO2018213151A1 (en) * 2017-05-18 2018-11-22 Merck Sharp & Dohme Corp. Pharmaceutical formulation comprising incretin-insulin conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803357B1 (en) * 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
US6960648B2 (en) * 2000-10-13 2005-11-01 Universite De Lausanne Intracellular delivery of biological effectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803357B1 (en) * 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
US6960648B2 (en) * 2000-10-13 2005-11-01 Universite De Lausanne Intracellular delivery of biological effectors

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018164B2 (en) 2005-11-07 2015-04-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8900593B2 (en) 2007-02-15 2014-12-02 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9447162B2 (en) 2007-02-15 2016-09-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US9487571B2 (en) 2010-01-27 2016-11-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
US9249206B2 (en) 2010-12-22 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity

Also Published As

Publication number Publication date
WO2008022015A2 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2008022015A3 (en) Retro-inverso incretin analogues, and methods of use thereof
US20160194371A1 (en) Fusion proteins comprising FGF-21 and GLP-1R agonist
Candeias et al. Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
CN104902919B (en) GLP1/GIP dual agonists or the triple agonists of GLP1/GIP/ glucagon
EP3080150B1 (en) Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
Martin et al. Incretin‐based therapies–review of the physiology, pharmacology and emerging clinical experience
Dixit et al. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis
WO2006024275A3 (en) Glp-1 and exendin related invention
NO20063436L (en) Intranasal administration of glucose regulatory peptides
EP2548570A1 (en) Pharmaceutical composition for treating a metabolic syndrome
CA2842133C (en) Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2005080433A3 (en) Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
MX2009006709A (en) Methods for the treatment of il-1ã¿ related diseases.
WO2007145941A8 (en) Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
WO2008033395A3 (en) Melanocortin and transferrin fusion proteins
WO2007140284A3 (en) N-terminally modified glp-1 receptor modulators
NO20082958L (en) Human glucagon-like peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2010092163A3 (en) Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
KR20210024583A (en) How to use GIP/GLP1 coagonists for therapy
Tanaka et al. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors
WO2007084544A3 (en) Methods of treating or preventing tissue damage caused by increased blood flow
WO2011163183A3 (en) Methods for delaying progression of diabetes using salacia oblonga extract
WO2016198604A1 (en) Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
McBrayer et al. Recent advances in GLP‐1 receptor agonists for use in diabetes mellitus
Li et al. GLP-1 and underlying beneficial actions in alzheimer’s disease, hypertension, and NASH

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07813979

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07813979

Country of ref document: EP

Kind code of ref document: A2